Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05533697 · ClinicalTrials.gov registry record · Phase 1
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors, sponsored by ModernaTX.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 361
- Enrollment target
- 20
- Study locations
NCT05533697: Recruiting Phase 1 study of Advanced Solid Tumors, sponsored by ModernaTX.
NCT05533697 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by ModernaTX. The registered enrollment target is 361 participants, above the 196-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (84% higher). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05533697, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by ModernaTX.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 361 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary goal of this study is to assess the safety and tolerability of mRNA-4359 administered alone and in combination with pembrolizumab or ipilimumab and nivolumab.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL Nivolumab
- BIOLOGICAL Ipilimumab
- BIOLOGICAL mRNA-4359
Study Locations (20)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
New South Wales
- Southside Cancer Center - Miranda
- Melanoma Institute Australia - Wollstonecraft
Other
- NEXT Oncology Barcelona - Barcelona
- NEXT Oncology Madrid - Madrid
California
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Colorado
- University of Colorado Cancer Center - Aurora
District of Columbia
- George Washington University - Washington D.C.
Florida
- Orlando Health UF Health Cancer Center - Orlando
Illinois
- The University of Chicago Medicine - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 361 participants |
| Start Date | 2022-09-01 |
| Est. Completion | 2032-02-18 |
| Phase | Phase 1 |
What NCT05533697 shows while recruiting
NCT05533697 is an interventional study that assigns participants to a tested intervention. The registered 361 participants enrollment target is mid-sized for trials with a published cap, above the 196-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (84% higher).
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT05533697 names 20 study sites across 17 states, led by Massachusetts, New South Wales, Other.
Frequently Asked Questions
What is clinical trial NCT05533697 about?
NCT05533697 is a clinical study titled "Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors". The primary goal of this study is to assess the safety and tolerability of mRNA-4359 administered alone and in combination with pembrolizumab or ipilimumab and nivolumab.
What is the current status of trial NCT05533697?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 361 participants. The study started on 2022-09-01. Estimated completion is 2032-02-18.
What conditions does trial NCT05533697 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT05533697?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Nivolumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL), mRNA-4359 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05533697?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05533697 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05533697's enrollment target sits among peer trials
361 19th of 144 higher than 126 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04988555 · 362 participants · Phase 1
A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation
- NCT05536141 · 362 participants · Phase 1
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
- NCT06534983 · 362 participants · Phase 2
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)
- NCT02747836 · 360 participants
Ultrasound Analysis of Human Carpal Tunnel System
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI